Moab Capital Partners’s Taro Pharmaceutical Industries Ltd. TARO Stock Holding History

Moab Capital Partners’s Portfolio TARO Stock Details TARO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-30,007	Closed	-$4.3M	–	32
2016 Q1	$4.3M	Buy	30,007 +802	+3%	+$114K	1.5%	15
2015 Q4	$4.51M	Sell	29,205 -80,482	-73%	-$11.8M	1.6%	17
2015 Q3	$15.7M	Buy	109,687 +8,006	+8%	+$1.12M	5.51%	5
2015 Q2	$14.6M	Buy	101,681 +24,724	+32%	+$3.53M	4.37%	5
2015 Q1	$10.9M	Sell	76,957 -2,600	-3%	-$400K	3.53%	7
2014 Q4	$11.8M	Buy	79,557 +16,137	+25%	+$2.37M	4.65%	6
2014 Q3	$9.76M	Sell	63,420 -29,713	-32%	-$4.47M	3.63%	11
2014 Q2	$13.1M	Sell	93,133 -300	-0.3%	-$33.3K	6.27%	5
2014 Q1	$10.4M	Buy	93,433 +10,301	+12%	+$1.12M	4.54%	9
2013 Q4	$8.22M	Sell	83,132 -3,178	-4%	-$276K	3.77%	8
2013 Q3	$6.56M	Buy	86,310 +32,000	+59%	+$2.08M	3.9%	10
2013 Q2	$3.04M	Buy	+54,310	New	+$3.21M	1.82%	17

Other funds holding TARO

Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

MICM

Matthews International Capital Management San Francisco, California $292M AUM 75.01% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $34.3B AUM 22.63% 1-Year Est. Return

Swiss National Bank Zurich, Switzerland $191B AUM 45.21% 1-Year Est. Return

Moab Capital Partners's TARO Position: Q2 2016 in Review

Moab Capital Partners sold out of Taro Pharmaceutical Industries Ltd. (TARO) in Q2 2016, closing a stake of 30,007 shares — an estimated $4.3M sold.

Moab Capital Partners first reported a position in TARO in Q2 2013 and held it in 12 quarters. The position peaked at $15.7M in Q3 2015. 159 funds tracked by Wall St. Rank hold TARO as of Q2 2016.

Moab Capital Partners reported no remaining Taro Pharmaceutical Industries Ltd. position as of Q2 2016 after selling out during the quarter.
Moab Capital Partners sold 30,007 Taro Pharmaceutical Industries Ltd. shares in Q2 2016, an estimated $4.3M.
Moab Capital Partners first reported a position in Taro Pharmaceutical Industries Ltd. in Q2 2013 and held it in 12 quarters.
Moab Capital Partners's Taro Pharmaceutical Industries Ltd. position peaked at $15.7M in Q3 2015.
159 funds tracked by Wall St. Rank held Taro Pharmaceutical Industries Ltd. as of Q2 2016.

Based on Moab Capital Partners's 13F filing for Q2 2016, filed 15 Aug 2016.